42.0.0.26 – Redirect Fix (Removed pre-redirect output)
DEBUG LOG – klik om te openen
=== VARIABELEN ===
Array
(
[defid] => VWS-WOO-08-1245692
[request_id] =>
)
=== SQL LOG ===
Geen SQL queries.
Huidig document record
Array
(
[id] => 069d72a6-e42c-4667-9cb1-751577b6db2a
[Document ID] => 1245692
[Document naam] => FYI - Covid-19 Vaccine AZ US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis
[Bestandsnaam] =>
[Beoordeling] =>
[Beoordelingsgrond] =>
[Toelichting] =>
[Publieke link] =>
[Locatie open.minvws.nl] => https://open.minvws.nl/dossier/VWS-WOO/3661708-1052463-pdo/document/VWS-WOO-08-1245692
[Opgeschort] =>
[Definitief ID] => VWS-WOO-08-1245692
[Status] =>
[FromFile] => https://open.minvws.nl/dossier/VWS-WOO/3661708-1052463-pdo
[DocumentPublicationDate] => 22 maart 2021
[DocumentStatusCheckedDate] =>
[DocumentStatusCheckedResult] =>
[SourceFileType] =>
[Tags] =>
[Besluit] =>
[ModifiedDate] => 2025-09-22 08:10:34
[DeletedDate] =>
[BesluitURL] =>
[CreatedDate] => 2025-06-19 18:31:59
[DocumentDownloadLink] =>
[DigestLaatsteControleDatum] => 2025-09-22 08:10:34
)
Document: VWS-WOO-08-1245692
Klik om te vergroten
Document correcties
Geregistreerde datum: 20210322
Geregistreerde documentnaam: FYI - Covid-19 Vaccine AZ US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis
Document attributen
| Tag | Waarde | Datum |
|---|---|---|
| About_Gelakte gegevens | 5.1.2e Eerbiediging van de persoonlijke levenssfeer Komt u in dit document gegevens tegen waarvan u denkt dat deze gelakt hadden moeten worden? Of is het document slecht leesbaar? Laat het ons weten | 2025-09-01 20:19:47 |
| About_Gelakte gegevens_linkhref_2 | mailto:DienstpostbusDatalekkenDoo@minvws.nl | 2025-09-01 20:19:47 |
| DocumentDownload_linkname | Download (pdf, 780.74 KB) | 2025-07-10 20:09:34 |
| DocumentDownload_linkhref | https://open.minvws.nl/dossier/VWS-WOO/3661708-1052463-pdo/file/download/document/1eec1b43-3811-65ca-a1ff-bb3705657b16 | 2025-07-10 20:09:34 |
| DocumentDownload_proposed_filename (lokale kopie) | VWS-WOO-08-1245692.pdf | 2025-07-10 20:09:34 |
| document_SectionDownloadButton | 1 | 2025-07-10 20:09:34 |
| document_SectionHistory | 1 | 2025-06-22 23:45:23 |
| About_Gelakte gegevens_linkname_1 | 5.1.2e Eerbiediging van de persoonlijke levenssfeer | 2025-06-22 23:45:23 |
| About_Gelakte gegevens_linkhref_2 | mailto:_dienstpostbusWoo-corona-ondersteuning@minvws.nl?subject=Opmerking over FYI - Covid-19 Vaccine AZ US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis (documentnummer 1eec1b43-3811-65ca-a1ff-bb3705657b16) | 2025-06-22 23:45:23 |
| About_Gelakte gegevens_linkname_2 | Laat het ons weten | 2025-06-22 23:45:23 |
| document_SectionRequest | 1 | 2025-06-22 23:45:23 |
| Request_Onderdeel van | Woo-deelbesluit aangaande Vaccinaties en Medicatie over de periode maart 2021 | 2025-06-22 23:45:23 |
| Request_Onderdeel van_linkhref_1 | https://open.minvws.nl/dossier/VWS-WOO/3661708-1052463-pdo | 2025-06-22 23:45:23 |
| Request_Onderdeel van_linkname_1 | Woo-deelbesluit aangaande Vaccinaties en Medicatie over de periode maart 2021 | 2025-06-22 23:45:23 |
| Request_Samenvatting verzoek | De minister van Volksgezondheid, Welzijn en Sport heeft op 23 november 2023 een besluit genomen op verzoeken in het kader van de Wet open overheid. Het besluit betreft openbaarmaking van documenten die betrekking hebben op informatie aangaande Vaccinaties & Medicatie maart 2021. | 2025-06-22 23:45:23 |
| Request_Periode | Maart 2021 | 2025-06-22 23:45:23 |
| Request_Type besluit | Woo-besluit | 2025-06-22 23:45:23 |
| Request_Datum besluit | 23 november 2023 | 2025-06-22 23:45:23 |
| Request_Omvang openbaarmaking | 15.961 documenten, 29.047 pagina's Inventarislijst | 2025-06-22 23:45:23 |
| Request_Omvang openbaarmaking_documenten | 15.961 | 2025-06-22 23:45:23 |
| Request_Omvang openbaarmaking_paginas | 29.047 | 2025-06-22 23:45:23 |
| Request_Omvang openbaarmaking_linkhref_1 | https://open.minvws.nl/dossier/VWS-WOO/3661708-1052463-pdo/file/download/inventory | 2025-06-22 23:45:23 |
| Request_Omvang openbaarmaking_linkname_1 | Inventarislijst | 2025-06-22 23:45:23 |
| document_documentName | FYI - Covid-19 Vaccine AZ US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis | 2025-06-22 23:45:23 |
| document_documentType | E-mailbericht | 2025-06-22 23:45:23 |
| document_documentPublicationDate | 2021-03-22 | 2025-06-22 23:45:23 |
| document_documentNumber | VWS-WOO-08-1245692 | 2025-06-22 23:45:23 |
| document_SectionDownloadButton | 0 | 2025-06-22 23:45:23 |
| document_SectionHTMLDataDivs | 3 | 2025-06-22 23:45:23 |
| document_SectionAbout | 1 | 2025-06-22 23:45:23 |
| About_Datum document | 22 maart 2021 | 2025-06-22 23:45:23 |
| About_Type bronbestand | E-mailbericht, 2 pagina's | 2025-06-22 23:45:23 |
| About_Type bronbestand_paginas | 2 | 2025-06-22 23:45:23 |
| About_Download als | PDF (780.74 KB) | 2025-06-22 23:45:23 |
| About_Documentnummer | 1245692 | 2025-06-22 23:45:23 |
| About_Beoordeling | Gedeeltelijke openbaarmaking | 2025-06-22 23:45:23 |
| About_Gelakte gegevens | 5.1.2e Eerbiediging van de persoonlijke levenssfeer Komt u in dit document gegevens tegen waarvan u denkt dat deze gelakt hadden moeten worden? Of is het document slecht leesbaar? Laat het ons weten. | 2025-06-22 23:45:23 |
| About_Gelakte gegevens_linkhref_1 | https://wetten.overheid.nl/BWBR0045754/2022-08-01#Hoofdstuk5 | 2025-06-22 23:45:23 |
| History Actie_2 | Bronbestand vervangen (pdf, 780.74 KB) | 2025-06-21 06:27:58 |
| History Datum_3 | 30 mei 2024 18:36 | 2025-06-21 06:27:58 |
| History Actie_3 | Bronbestand vervangen (pdf, 780.74 KB) | 2025-06-21 06:27:58 |
| History Datum_4 | 30 mei 2024 18:21 | 2025-06-21 06:27:58 |
| History Actie_4 | Bronbestand vervangen (pdf, 780.74 KB) | 2025-06-21 06:27:58 |
| History Datum_5 | 30 mei 2024 16:50 | 2025-06-21 06:27:58 |
| History Actie_5 | Bronbestand vervangen (pdf, 780.74 KB) | 2025-06-21 06:27:58 |
| History Datum_6 | 30 mei 2024 16:36 | 2025-06-21 06:27:58 |
| History Actie_6 | Bronbestand vervangen (pdf, 780.74 KB) | 2025-06-21 06:27:58 |
| History Datum_7 | 30 mei 2024 15:03 | 2025-06-21 06:27:58 |
| History Actie_7 | Bronbestand vervangen (pdf, 780.74 KB) | 2025-06-21 06:27:58 |
| History Datum_8 | 30 mei 2024 14:51 | 2025-06-21 06:27:58 |
| History Actie_8 | Bronbestand toegevoegd (pdf, 780.74 KB) | 2025-06-21 06:27:58 |
| History Datum_2 | 30 mei 2024 19:14 | 2025-06-21 06:27:58 |
| History Actie_1 | Bronbestand vervangen (pdf, 780.74 KB) | 2025-06-21 06:27:58 |
| History Datum_1 | 30 mei 2024 19:18 | 2025-06-21 06:27:58 |
Archiefversies (6 rijen)
Archiefrij 1 — 2025-09-07 17:26:07
fromFile: folder_import
fromFilePath: /volume3/websites/openrijksoverheid/documenten_files/VWS-WOO-08-1245692.pdf
documentName: VWS-WOO-08-1245692.pdf
documentType: pdf
documentCompressedSize: 0
documentSize: 799479
documentCompressRatio: 0
documentDateModified: 2025-09-07 17:26:07
dossierReference: leeg!
dossierReferenceAlias: leeg!
createdDate: 2025-09-07 17:26:07
lastSeen: 2025-09-07 17:26:07
text: 1245692
ETEXEEEiv.1:EEE)EENERIEvr;EEEIEEEEERvmTo:
@rivm.nl
Cc:gS512 S512@astrazeneca.com]
From:N5.1.2e p12
Sent:Mon 3/22/2021 7:36:51 AM
Subject: FYI-Covid-19 Vaccine AZUSPhase llltrial met primary efficacy endpoint inpreventing COVID-19 atinterim analysis
Received:Mon 3/22/2021 7:36:59 AM
Beste all...
noTextDate: leeg!
ocrText: leeg!
documentIndicatedDate: leeg!
documentIndicatedDateCorrected: leeg!
documentMailAddresses: leeg!
documentMailAdresses: leeg!
digestSHA256: 1fbb615376b169098ee357f303ec17b5d6c2ff9861dbcfd15056c611454ea1ca
documentDate: leeg!
ModifiedDate: 2025-12-10 19:41:04.555019+00
Id: folder_import_48242_97a1d2cad7449b556e01c126a7e666d7
textDigestSHA256: a13c3409523372cc6f45e2d0114385c4b4ab044d41454635ade2337bfd04da75
ocrTextDigestSHA256: leeg!
extractedId: VWS-WOO-08-1245692
Archiefrij 2 — 2025-09-04 17:12:23
fromFile: VWS-WOO-3661708-1052463-pdo-1f026c98-ad58-69b6-b436-65673e0af118.zip
fromFilePath: ../../archieven_files/VWS-WOO-3661708-1052463-pdo-1f026c98-ad58-69b6-b436-65673e0af118.zip
documentName: VWS-WOO-08-1245692.pdf
documentType: pdf
documentCompressedSize: 511905
documentSize: 799479
documentCompressRatio: 64.02982442315557
documentDateModified: 2025-05-01 20:46:00
dossierReference: leeg!
dossierReferenceAlias: leeg!
createdDate: 2025-09-04 17:12:23
lastSeen: 2025-09-04 17:12:23
text: 1245692 ET To: EXE EE iv. 1: EEE) EEN ERIE @rivm.nl Cc: S512 g From: N Sent: 5.1.2e S512 vr; EEE IEEE EER vm @astrazeneca.com] p12 Mon 3/22/2021 7:36:51 AM FYI Subject: - Received: Covid-19 Vaccine AZ US Phase lll trial met primary effi...
noTextDate: leeg!
ocrText: 1227720 Artikel ArtikeIType, ArtikelFarmaceut ArtikelDescription ArtikelCategorie ArtikelAantal ArtikelEenheid, ArtikelHoeveelheid, ArtikelHoeveelheid Flacons,ArtikelHoeveelheidDosesPerTray ArtikelHoeveelheidDoses, ArtikelAfnemer ArtikelAfnemerGroep, ArtikelAfgiftedatum , ArtikelStatus, ArtikelAfze...
documentIndicatedDate: leeg!
documentIndicatedDateCorrected: leeg!
documentMailAddresses: leeg!
documentMailAdresses: leeg!
digestSHA256: 1fbb615376b169098ee357f303ec17b5d6c2ff9861dbcfd15056c611454ea1ca
documentDate: leeg!
ModifiedDate: 2025-12-10 19:42:10.749631+00
Id: VWS-WOO-3661708-1052463-pdo-1f026c98-ad58-69b6-b436-65673e0af118.zip_6190
textDigestSHA256: 4102f6eb6b317d45e907f7bcd9dceb5f3b0a5959eaa9961b7cf056258a900d89
ocrTextDigestSHA256: cbb318e36bc801b51a4e835f266ccf9e2f2591f7587882f9cceab6e8131f83fb
extractedId: VWS-WOO-08-1245692
Archiefrij 3 — 2025-09-04 17:10:20
fromFile: VWS-WOO-3661708-1052463-pdo-1f019da5-31c3-6fd4-91a7-fda7571a98e0.zip
fromFilePath: ../../archieven_files/VWS-WOO-3661708-1052463-pdo-1f019da5-31c3-6fd4-91a7-fda7571a98e0.zip
documentName: VWS-WOO-08-1245692.pdf
documentType: pdf
documentCompressedSize: 511905
documentSize: 799479
documentCompressRatio: 64.02982442315557
documentDateModified: 2025-05-01 20:46:00
dossierReference: leeg!
dossierReferenceAlias: leeg!
createdDate: 2025-09-04 17:10:20
lastSeen: 2025-09-04 17:10:20
text: 1245692 ET To: EXE EE iv. 1: EEE) EEN ERIE @rivm.nl Cc: S512 g From: N Sent: 5.1.2e S512 vr; EEE IEEE EER vm @astrazeneca.com] p12 Mon 3/22/2021 7:36:51 AM FYI Subject: - Received: Covid-19 Vaccine AZ US Phase lll trial met primary effi...
noTextDate: leeg!
ocrText: isoweek-2021 isoweek-2022 |Ct-waarde 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-...
documentIndicatedDate: leeg!
documentIndicatedDateCorrected: leeg!
documentMailAddresses: leeg!
documentMailAdresses: leeg!
digestSHA256: 1fbb615376b169098ee357f303ec17b5d6c2ff9861dbcfd15056c611454ea1ca
documentDate: leeg!
ModifiedDate: 2025-12-10 19:42:10.749631+00
Id: VWS-WOO-3661708-1052463-pdo-1f019da5-31c3-6fd4-91a7-fda7571a98e0.zip_6190
textDigestSHA256: 4102f6eb6b317d45e907f7bcd9dceb5f3b0a5959eaa9961b7cf056258a900d89
ocrTextDigestSHA256: 34ea7743594f08b217c2e155c1f4035ef17e172d69327d310aa73507055b967b
extractedId: VWS-WOO-08-1245692
Archiefrij 4 — 2025-03-18 09:30:26
fromFile: 2024.075-VWS-WOO-3661708-1052463-pdo.zip
fromFilePath: Z:\ARCHIEF WOO Documenten\archieven_files\2024.075-VWS-WOO-3661708-1052463-pdo.zip
documentName: VWS-WOO-08-1245692-FYI_-_Covid-19_Vaccine_AZ__US_Phase_III_trial_met_primary_efficacy_endpoint_in_preventing_COVID-19_at_interim_analysis.pdf
documentType: pdf
documentCompressedSize: 510545
documentSize: 799479
documentCompressRatio: 63.859713638507074
documentDateModified: 2024-10-25 13:30:24
dossierReference: leeg!
dossierReferenceAlias: leeg!
createdDate: 2025-03-18 09:30:26
lastSeen: 2025-03-18 09:30:26
text: 1245692
ETEXEEEiv.1:EEE)EENERIEvr;EEEIEEEEERvmTo:
@rivm.nl
Cc:gS512 S512@astrazeneca.com]
From:N5.1.2e p12
Sent:Mon 3/22/2021 7:36:51 AM
Subject: FYI-Covid-19 Vaccine AZUSPhase llltrial met primary efficacy endpoint inpreventing COVID-19 atinterim analysis
Received:Mon 3/22/2021 7:36:59 AM
Beste all...
noTextDate: leeg!
ocrText: leeg!
documentIndicatedDate: leeg!
documentIndicatedDateCorrected: leeg!
documentMailAddresses: leeg!
documentMailAdresses: leeg!
digestSHA256: a13c3409523372cc6f45e2d0114385c4b4ab044d41454635ade2337bfd04da75
documentDate: leeg!
ModifiedDate: 2025-12-10 19:41:04.555019+00
Id: 355271
textDigestSHA256: a13c3409523372cc6f45e2d0114385c4b4ab044d41454635ade2337bfd04da75
ocrTextDigestSHA256: leeg!
extractedId: VWS-WOO-08-1245692
Archiefrij 5 — 2025-02-27 09:25:06
fromFile: 2022.252-VWS-WOO-3661708-1052463-pdo.zip
fromFilePath: Z:\ARCHIEF WOO Documenten\archieven_files\2022.252-VWS-WOO-3661708-1052463-pdo.zip
documentName: VWS-WOO-08-1245692-FYI_-_Covid-19_Vaccine_AZ__US_Phase_III_trial_met_primary_efficacy_endpoint_in_preventing_COVID-19_at_interim_analysis.pdf
documentType: pdf
documentCompressedSize: 510545
documentSize: 799479
documentCompressRatio: 63.859713638507074
documentDateModified: 2024-10-25 13:30:24
dossierReference: leeg!
dossierReferenceAlias: leeg!
createdDate: 2025-02-27 09:25:06
lastSeen: 2025-02-27 09:25:06
text: 1245692
ETEXEEEiv.1:EEE)EENERIEvr;EEEIEEEEERvmTo:
@rivm.nl
Cc:gS512 S512@astrazeneca.com]
From:N5.1.2e p12
Sent:Mon 3/22/2021 7:36:51 AM
Subject: FYI-Covid-19 Vaccine AZUSPhase llltrial met primary efficacy endpoint inpreventing COVID-19 atinterim analysis
Received:Mon 3/22/2021 7:36:59 AM
Beste all...
noTextDate: leeg!
ocrText: leeg!
documentIndicatedDate: leeg!
documentIndicatedDateCorrected: leeg!
documentMailAddresses: [{"position": 50, "email": "@rivm.nl", "context": "1245692 ETEXEEEiv.1:EEE)EENERIEvr;EEEIEEEEERvmTo: @rivm.nl Cc:gS512 S512@astrazeneca.com] From:N5.1.2e"}, {"position": 68, "email": "S512@astrazeneca.com", "context": "ETEXEEEiv.1:EEE)EENERIEvr;EEEIEEEEERvmTo: @rivm.nl Cc:gS512 S512@astrazeneca.com] From:N5.1.2e p12 Sent:Mon"}]
documentMailAdresses: [{"position": 50, "email": "@rivm.nl", "context": "1245692 ETEXEEEiv.1:EEE)EENERIEvr;EEEIEEEEERvmTo: @rivm.nl Cc:gS512 S512@astrazeneca.com] From:N5.1.2e"}, {"position": 68, "email": "S512@astrazeneca.com", "context": "ETEXEEEiv.1:EEE)EENERIEvr;EEEIEEEEERvmTo: @rivm.nl Cc:gS512 S512@astrazeneca.com] From:N5.1.2e p12 Sent:Mon"}]
digestSHA256: a13c3409523372cc6f45e2d0114385c4b4ab044d41454635ade2337bfd04da75
documentDate: leeg!
ModifiedDate: 2025-12-10 19:41:04.555019+00
Id: 268441
textDigestSHA256: a13c3409523372cc6f45e2d0114385c4b4ab044d41454635ade2337bfd04da75
ocrTextDigestSHA256: leeg!
extractedId: VWS-WOO-08-1245692
Archiefrij 6 — 2025-02-18 12:18:04
fromFile: Besluit__dossier_nr_-8b6498f524850c599dea15620ecff89d59609350ff716d119d38634615d4d862.zip
fromFilePath: Z:\ARCHIEF WOO Documenten\archieven_files\Besluit__dossier_nr_-8b6498f524850c599dea15620ecff89d59609350ff716d119d38634615d4d862.zip
documentName: VWS-WOO-08-1245692-FYI_-_Covid-19_Vaccine_AZ__US_Phase_III_trial_met_primary_efficacy_endpoint_in_preventing_COVID-19_at_interim_analysis.pdf
documentType: pdf
documentCompressedSize: 510545
documentSize: 799479
documentCompressRatio: 63.859713638507074
documentDateModified: 2024-10-25 13:30:24
dossierReference: leeg!
dossierReferenceAlias: leeg!
createdDate: 2025-02-18 12:18:04
lastSeen: 2025-02-18 12:18:04
text: 1245692
ETEXEEEiv.1:EEE)EENERIEvr;EEEIEEEEERvmTo:
@rivm.nl
Cc:gS512 S512@astrazeneca.com]
From:N5.1.2e p12
Sent:Mon 3/22/2021 7:36:51 AM
Subject: FYI-Covid-19 Vaccine AZUSPhase llltrial met primary efficacy endpoint inpreventing COVID-19 atinterim analysis
Received:Mon 3/22/2021 7:36:59 AM
Beste all...
noTextDate: leeg!
ocrText: leeg!
documentIndicatedDate: leeg!
documentIndicatedDateCorrected: leeg!
documentMailAddresses: [{"position": 50, "email": "@rivm.nl", "context": "1245692 ETEXEEEiv.1:EEE)EENERIEvr;EEEIEEEEERvmTo: @rivm.nl Cc:gS512 S512@astrazeneca.com] From:N5.1.2e"}, {"position": 68, "email": "S512@astrazeneca.com", "context": "ETEXEEEiv.1:EEE)EENERIEvr;EEEIEEEEERvmTo: @rivm.nl Cc:gS512 S512@astrazeneca.com] From:N5.1.2e p12 Sent:Mon"}]
documentMailAdresses: [{"position": 50, "email": "@rivm.nl", "context": "1245692 ETEXEEEiv.1:EEE)EENERIEvr;EEEIEEEEERvmTo: @rivm.nl Cc:gS512 S512@astrazeneca.com] From:N5.1.2e"}, {"position": 68, "email": "S512@astrazeneca.com", "context": "ETEXEEEiv.1:EEE)EENERIEvr;EEEIEEEEERvmTo: @rivm.nl Cc:gS512 S512@astrazeneca.com] From:N5.1.2e p12 Sent:Mon"}]
digestSHA256: a13c3409523372cc6f45e2d0114385c4b4ab044d41454635ade2337bfd04da75
documentDate: leeg!
ModifiedDate: 2025-12-10 19:40:42.137456+00
Id: 57577
textDigestSHA256: a13c3409523372cc6f45e2d0114385c4b4ab044d41454635ade2337bfd04da75
ocrTextDigestSHA256: leeg!
extractedId: VWS-WOO-08-1245692
(dit is ook een speeltuin)